Brown V - Search Results

1

Interleukin 15 mediates epithelial changes in celiac disease.

Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, Londei M. Maiuri L, et al. Among authors: brown v. Gastroenterology. 2000 Oct;119(4):996-1006. doi: 10.1053/gast.2000.18149. Gastroenterology. 2000. PMID: 11040186

2

Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.

Brown VI, Hulitt J, Fish J, Sheen C, Bruno M, Xu Q, Carroll M, Fang J, Teachey D, Grupp SA. Brown VI, et al. Cancer Res. 2007 Oct 15;67(20):9963-70. doi: 10.1158/0008-5472.CAN-06-4704. Cancer Res. 2007. PMID: 17942929

3

Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation.

Bitan M, Ahn KW, Millard HR, Pulsipher MA, Abdel-Azim H, Auletta JJ, Brown V, Chan KW, Diaz MA, Dietz A, Vincent MG, Guilcher G, Hale GA, Hayashi RJ, Keating A, Mehta P, Myers K, Page K, Prestidge T, Shah NN, Smith AR, Woolfrey A, Thiel E, Davies SM, Eapen M. Bitan M, et al. Among authors: brown v. Biol Blood Marrow Transplant. 2017 Sep;23(9):1523-1530. doi: 10.1016/j.bbmt.2017.05.011. Epub 2017 May 17. Biol Blood Marrow Transplant. 2017. PMID: 28527984 Free PMC article.

4

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT. Barrett D, et al. Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Paediatr Drugs. 2012. PMID: 22845486 Free PMC article. Review.

5

Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses.

Seif AE, Barrett DM, Milone M, Brown VI, Grupp SA, Reid GS. Seif AE, et al. Blood. 2009 Sep 17;114(12):2459-66. doi: 10.1182/blood-2009-02-203984. Epub 2009 Jul 27. Blood. 2009. PMID: 19636062 Free PMC article.

6

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Teachey DT, Grupp SA, Brown VI. Teachey DT, et al. Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. Br J Haematol. 2009. PMID: 19344392 Free PMC article. Review.

7

Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Brown VI, Seif AE, Reid GS, Teachey DT, Grupp SA. Brown VI, et al. Immunol Res. 2008;42(1-3):84-105. doi: 10.1007/s12026-008-8038-9. Immunol Res. 2008. PMID: 18716718 Free PMC article. Review.

8

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.

Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J, Reid GS, Seif AE, Norris R, Chang YJ, Carroll M, Grupp SA. Teachey DT, et al. Blood. 2008 Sep 1;112(5):2020-3. doi: 10.1182/blood-2008-02-137141. Epub 2008 Jun 10. Blood. 2008. PMID: 18544682 Free PMC article.

9

Targeting Notch signaling in autoimmune and lymphoproliferative disease.

Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang YJ, Choi JK, Fish JD, Hall J, Reid GS, Ryan T, Sheen C, Zweidler-McKay P, Grupp SA. Teachey DT, et al. Blood. 2008 Jan 15;111(2):705-14. doi: 10.1182/blood-2007-05-087353. Epub 2007 Oct 9. Blood. 2008. PMID: 17925488 Free PMC article.

10

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.

Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA. Teachey DT, et al. Blood. 2006 Feb 1;107(3):1149-55. doi: 10.1182/blood-2005-05-1935. Epub 2005 Sep 29. Blood. 2006. PMID: 16195324 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results